{"drugs":["Iplex","Mecasermin Rinfabate"],"mono":{"0":{"id":"928479-s-0","title":"Generic Names","mono":"Mecasermin Rinfabate"},"1":{"id":"928479-s-1","title":"Dosing and Indications","sub":{"1":{"id":"928479-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>Primary IGF-1 deficiency (Severe):<\/b> initial, 0.5 mg\/kg SUBQ once daily<\/li><li><b>Primary IGF-1 deficiency (Severe):<\/b> maintenance, 1 to 2 mg\/kg SUBQ once daily; MAX 2 mg\/kg daily; reduce dose if adverse events occur including hypoglycemia and\/or IGF-1 levels that are greater than or equal to 3 standard deviation above the normal reference range for insulin-like growth factor-1<\/li><\/ul>"},"2":{"id":"928479-s-1-6","title":"Dose Adjustments","mono":"<ul><li>undetectable acid-labile subunit (ALS) levels at baseline may require higher mecasermin doses<\/li><li>reduce dose if adverse events occur including hypoglycemia<\/li><li>reduce dose if IGF-1 levels that are greater than or equal to 3 standard deviation above the normal reference range for insulin-like growth factor-1<\/li><\/ul>"},"3":{"id":"928479-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Primary IGF-1 deficiency (Severe)<br\/>"}}},"3":{"id":"928479-s-3","title":"Contraindications\/Warnings","sub":[{"id":"928479-s-3-9","title":"Contraindications","mono":"<ul><li>allergy to mecasermin rinfabate or any component of the formulation<\/li><li>closed epiphyses; should not be used for growth promotion<\/li><li>intravenous administration<\/li><li>neoplasia, active or suspected; discontinue therapy if neoplasia subsequently develops<\/li><\/ul>"},{"id":"928479-s-3-10","title":"Precautions","mono":"<ul><li>high-risk activities; limit activities until tolerability has been established due to hypoglycemic effect<\/li><li>hypoglycemic effect, especially in small children because of unpredictable oral intake; administer shortly before or after a meal or snack<\/li><li>intracranial hypertension with papilledema may occur<\/li><li>lymphoid tissue hypertrophy, tonsillar and adenoidal; may result in complications such as excessive snoring, sleep apnea, chronic middle ear effusions, hearing loss<\/li><li>scoliosis; progression due to rapid growth<\/li><li>sensitivity or allergic reactions may occur; discontinue treatment<\/li><li>should be used only by physicians experienced in the diagnosis and management of patients with grow disorders<\/li><li>slipped capital femoral epiphysis may occur with rapid growth<\/li><\/ul>"},{"id":"928479-s-3-11","title":"Pregnancy Category","mono":"Mecasermin: C (FDA)<br\/>"},{"id":"928479-s-3-12","title":"Breast Feeding","mono":"Mecasermin: Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"928479-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Injection site reaction (5% or more)<\/li><li><b>Endocrine metabolic:<\/b>Goiter (5% or more), Hyperglycemia (5% or more), Hypoglycemia (Mild) (31%)<\/li><li><b>Hematologic:<\/b>Iron deficiency anemia (5% or more)<\/li><li><b>Hepatic:<\/b>Elevated levels of transaminase &amp; lactic acid dehydrogenase (Mild) (5% or more)<\/li><li><b>Immunologic:<\/b>Antibody development (90%), Hypertrophy of adenoids (19%), Hypertrophy of tonsils (19%), Lymphadenopathy (5% or more)<\/li><li><b>Musculoskeletal:<\/b>Arthralgia (5% or more), Bone pain (5% or more), Muscle atrophy (5% or more), Pain in limb (5% or more)<\/li><li><b>Neurologic:<\/b>Headache (22%)<\/li><li><b>Ophthalmic:<\/b>Optic disc edema (5% or more)<\/li><li><b>Renal:<\/b>Hematuria (5% or more)<\/li><li><b>Reproductive:<\/b>Cyst of ovary (5.5%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Endocrine metabolic:<\/b>Hypoglycemia (Severe) (5.5%)<\/li><li><b>Neurologic:<\/b>Raised intracranial pressure<\/li><\/ul>"},"6":{"id":"928479-s-6","title":"Drug Name Info","sub":{"0":{"id":"928479-s-6-17","title":"US Trade Names","mono":"Iplex<br\/>"},"2":{"id":"928479-s-6-19","title":"Class","mono":"Endocrine-Metabolic Agent<br\/>"},"3":{"id":"928479-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"9":{"id":"928479-s-9","title":"Administration","mono":"<b>Subcutaneous<\/b><br\/><ul><li>for SUBQ use only; do not administer IV<\/li><li>patient should maintain a balanced diet; do not administer if the patient cannot or will not eat or if a meal is skipped<\/li><li>administer in the morning or evening at approximately the same time every day<\/li><li>withhold doses if signs or symptoms of hypoglycemia are present at the time of dosing<\/li><li>subsequent doses should not be increased to make up for a missed dose<\/li><li>injection site should be rotated to a different site with each injection; new injections should be given at least one inch from the previous injection site(s); do not inject into areas where the skin is tender, bruised, red, hard, or lipodystrophic<\/li><li>should be administered using sterile disposable syringes and needles via aseptic technique<\/li><li>thaw to room temperature by using hands to warm vial for approximately 2 minutes; do not administer until at room temperature; discard any unused portion<\/li><li>do not shake vial; swirl in a gentle rotary motion to ensure complete mixing<\/li><\/ul>"},"10":{"id":"928479-s-10","title":"Monitoring","mono":"<ul><li>acromegaly<\/li><li>blood glucose at initiation and when a dose is increased.<\/li><li>fundoscopic examinations at initiation and periodically (detect papilledema-related intracranial hypertension)<\/li><li>height velocity; should increase at least 2 centimeters\/year<\/li><li>insulin-like growth factor-1 levels 8 to 18 hours after the previous dose; target levels are 0 to +2 standard deviation score for age<\/li><li>lymphoid tissue examinations, periodically (detect hypertrophy)<\/li><li>progression of scoliosis with rapid growth<\/li><li>signs and symptoms of intracranial hypertension such as visual changes, headache, and nausea and\/or vomiting<\/li><li>Slipped capital femoral epiphysis with rapid growth.<\/li><li>undetectable acid-labile subunit (ALS) levels at baseline.<\/li><\/ul>"},"13":{"id":"928479-s-13","title":"Clinical Teaching","mono":"<ul><li>Patient should avoid high-risk activities requiring coordination until drug effects are realized.<\/li><li>This drug may cause goiter, hypertrophy of tonsils\/adenoids, lymphadenopathy, arthralgia, bone pain, pain in limbs, or hematuria.<\/li><li>Advise patient to report signs\/symptoms of slipped capital femoral epiphysis (limp or pain, stiffness, limited movement of hip) or raised intracranial hypertension (visual changes, headache, nausea, vomiting).<\/li><li>Drug may cause hypo- or hyperglycemia. Instruct patients to monitor for and report severe or persistent hypoglycemia.<\/li><li>Patient should take drug within 20 min before or after a meal or snack. Advise patient to not take drug when a meal is skipped, as this may cause hypoglycemic effects.<\/li><li>Teach patient proper technique and placement of injections.<\/li><li>Advise patient to rotate injection sites.<\/li><\/ul>"}}}